Behandling af våd aldersrelateret makuladegeneration med vaskulaer endotel vaekstfaktorhaemmer. Gennemgang af et Cochrane-review

Sara Brandi Bloch; Michael Larsen; Sara Brandi Bloch; Michael Larsen

Behandling af våd aldersrelateret makuladegeneration med vaskulaer endotel vaekstfaktorhaemmer. Gennemgang af et Cochrane-review

Sara Brandi Bloch, Michael Larsen, Sara Brandi Bloch, Michael Larsen

Abstract

This evaluation of a Cochrane-review including five clinical trials of good methodological quality indicates that the antiangiogenic therapeutic agents, pegaptanib and ranibizumab, are effective treatment strategies for neovascular Age-Related Macular Degeneration (AMD). The review does not include a direct comparison or an indirect statistical comparison between the two antiangiogenic agents. In clinical practice ranibizumab compared to pegaptanib is the drug of choice because of cost-utility analysis and the number of patients gaining visual acuity.
Udgivelsesdato: 2009-Nov

Bidragets oversatte titel	Treatment of wet age-related macular degeneration with vascular endothelial growth factor. A survey of a Cochrane review
Originalsprog	Dansk
Tidsskrift	Ugeskrift for læger
Vol/bind	171
Udgave nummer	47
Sider (fra-til)	3435-7
Antal sider	3
ISSN	0041-5782
Status	Udgivet - 16 nov. 2009

Citationsformater

@article{3d22f01088cc11df928f000ea68e967b,

title = "Behandling af v{\aa}d aldersrelateret makuladegeneration med vaskulaer endotel vaekstfaktorhaemmer. Gennemgang af et Cochrane-review",

abstract = "This evaluation of a Cochrane-review including five clinical trials of good methodological quality indicates that the antiangiogenic therapeutic agents, pegaptanib and ranibizumab, are effective treatment strategies for neovascular Age-Related Macular Degeneration (AMD). The review does not include a direct comparison or an indirect statistical comparison between the two antiangiogenic agents. In clinical practice ranibizumab compared to pegaptanib is the drug of choice because of cost-utility analysis and the number of patients gaining visual acuity. Udgivelsesdato: 2009-Nov",

author = "Bloch, {Sara Brandi} and Michael Larsen and Bloch, {Sara Brandi} and Michael Larsen",

note = "Keywords: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Aptamers, Nucleotide; Evidence-Based Medicine; Humans; Porphyrins; Treatment Outcome; Vascular Endothelial Growth Factor A; Wet Macular Degeneration",

year = "2009",

month = nov,

day = "16",

language = "Dansk",

volume = "171",

pages = "3435--7",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "47",

}

TY - JOUR

T1 - Behandling af våd aldersrelateret makuladegeneration med vaskulaer endotel vaekstfaktorhaemmer. Gennemgang af et Cochrane-review

AU - Bloch, Sara Brandi

AU - Larsen, Michael

AU - Bloch, Sara Brandi

AU - Larsen, Michael

N1 - Keywords: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Aptamers, Nucleotide; Evidence-Based Medicine; Humans; Porphyrins; Treatment Outcome; Vascular Endothelial Growth Factor A; Wet Macular Degeneration

PY - 2009/11/16

Y1 - 2009/11/16

N2 - This evaluation of a Cochrane-review including five clinical trials of good methodological quality indicates that the antiangiogenic therapeutic agents, pegaptanib and ranibizumab, are effective treatment strategies for neovascular Age-Related Macular Degeneration (AMD). The review does not include a direct comparison or an indirect statistical comparison between the two antiangiogenic agents. In clinical practice ranibizumab compared to pegaptanib is the drug of choice because of cost-utility analysis and the number of patients gaining visual acuity. Udgivelsesdato: 2009-Nov

AB - This evaluation of a Cochrane-review including five clinical trials of good methodological quality indicates that the antiangiogenic therapeutic agents, pegaptanib and ranibizumab, are effective treatment strategies for neovascular Age-Related Macular Degeneration (AMD). The review does not include a direct comparison or an indirect statistical comparison between the two antiangiogenic agents. In clinical practice ranibizumab compared to pegaptanib is the drug of choice because of cost-utility analysis and the number of patients gaining visual acuity. Udgivelsesdato: 2009-Nov

M3 - Review

SN - 0041-5782

VL - 171

SP - 3435

EP - 3437

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 47

ER -

Behandling af våd aldersrelateret makuladegeneration med vaskulaer endotel vaekstfaktorhaemmer. Gennemgang af et Cochrane-review

Abstract

Fingeraftryk

Citationsformater